<DOC>
	<DOCNO>NCT02250404</DOCNO>
	<brief_summary>This pilot research trial study molecular signature return cancer period improvement ( relapse ) tissue sample patient small cell lung cancer receive plan receive cisplatin etoposide . Studying sample tissue patient small cell lung cancer laboratory may help doctor learn change occur deoxyribonucleic acid ( DNA ) identify biomarkers related cancer relapse .</brief_summary>
	<brief_title>Molecular Signatures Relapse Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin Etoposide</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To collect analyze small cell lung cancer ( SCLC ) tumor DNA ribonucleic acid ( RNA ) 3 human patient relapse identify molecular signature relapse . OUTLINE : Previously collect tissue sample analyze via RNA sequence DNA methylation baseline . Patients also undergo collection tissue sample analysis relapse .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Any patient see Norris County histologically confirm SCLC , tissue Norris Cancer Center Tumor Repository Patients must undergo start first line treatment cisplatin etoposide Patients may second malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>